When the CPG2 recombinant adenovirus is used in combination with the prodrug ZD2767P, it significantly increases the sensitivity of tumour cells to the latter; (3) anti-tumour angiogenesis genes could also be carried by the oncolytic virus to inhibit tumour progression. This evidence concerns the gene SYNE1 and neoplasm.